Pharma and Biotech Daily: Novo's Licensing Deal, FDA's Cancer Drug Development Shift, and More!
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Novo has licensed the potential first-in-class antibody candidate to Almirall, granting them exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828. The FDA's shift towards overall survival in cancer drug development is anticipated to have a significant impact, particularly on small biotechs. Moreover, the FDA recently greenlit the first one-time cell therapy for a solid tumor and expanded Tagrisso's label for non-small cell lung cancer. Cancer remains a complex disease, with companies like Bristol Myers Squibb focusing on creating diverse therapeutic options using advanced modalities to combat it. In other news, the FDA has accepted a BLA for an ADC for NSCLC from AstraZeneca and Daiichi Sankyo, while Sanofi and Denali's ALS candidate did not succeed in a mid-stage trial. Opportunities in the biotech industry are available for those interested. Stay informed with relevant updates from Biospace by managing your preferences.
